EA201390812A1 - Лиофилизированные вирусные составы - Google Patents
Лиофилизированные вирусные составыInfo
- Publication number
- EA201390812A1 EA201390812A1 EA201390812A EA201390812A EA201390812A1 EA 201390812 A1 EA201390812 A1 EA 201390812A1 EA 201390812 A EA201390812 A EA 201390812A EA 201390812 A EA201390812 A EA 201390812A EA 201390812 A1 EA201390812 A1 EA 201390812A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- lyophylized
- virus
- virus compositions
- compositions
- viruses
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 241000700605 Viruses Species 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 abstract 3
- 230000003612 virological effect Effects 0.000 abstract 3
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12251—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41902010P | 2010-12-02 | 2010-12-02 | |
| PCT/US2011/063037 WO2012075376A2 (en) | 2010-12-02 | 2011-12-02 | Lyophilized viral formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201390812A1 true EA201390812A1 (ru) | 2013-11-29 |
Family
ID=46162458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201390812A EA201390812A1 (ru) | 2010-12-02 | 2011-12-02 | Лиофилизированные вирусные составы |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9044498B2 (https=) |
| EP (1) | EP2646052B1 (https=) |
| JP (3) | JP6034797B2 (https=) |
| KR (1) | KR102023207B1 (https=) |
| CN (1) | CN103269716B (https=) |
| AU (1) | AU2011336410B2 (https=) |
| CA (1) | CA2819236A1 (https=) |
| DK (1) | DK2646052T3 (https=) |
| EA (1) | EA201390812A1 (https=) |
| ES (1) | ES2630012T3 (https=) |
| IL (1) | IL226646B (https=) |
| MX (1) | MX349294B (https=) |
| SG (1) | SG190419A1 (https=) |
| TW (1) | TW201233803A (https=) |
| WO (1) | WO2012075376A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5577103B2 (ja) * | 2007-03-12 | 2014-08-20 | オンコリティクス バイオテク，インコーポレーテッド | 改変配列を有するレオウイルス |
| AU2011336413B2 (en) * | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
| MX349294B (es) * | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Formulaciones virales liofilizadas. |
| JP6029651B2 (ja) * | 2011-04-29 | 2016-11-24 | オンコリティクス バイオテク，インコーポレーテッド | ゲル浸透クロマトグラフィーを使用してウイルスを精製する方法 |
| US11273127B2 (en) | 2014-05-06 | 2022-03-15 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for thermally stable multi-targeted antigens |
| GB201513010D0 (en) * | 2015-07-23 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel formulation |
| PT3534922T (pt) * | 2016-11-04 | 2024-06-07 | Takeda Pharmaceuticals Co | Formulações de vírus adenoassociado |
| CN111655844B (zh) * | 2017-10-16 | 2024-05-24 | 印度血清研究所私人有限公司 | 包含特别是减毒活重组黄病毒的稳定的疫苗组合物及其制备方法 |
| AU2019299964A1 (en) | 2018-07-11 | 2021-01-21 | Takeda Pharmaceutical Company Limited | AAV compositions |
| CN110279693B (zh) * | 2019-07-25 | 2021-06-15 | 军事科学院军事医学研究院微生物流行病研究所 | 一种组合物在制备预防和/或治疗发热伴血小板减少综合征病毒的药物中的应用 |
| CN112107678B (zh) * | 2020-09-30 | 2022-11-18 | 辰欣药业股份有限公司 | 一种含有胸腺法新的冻干组合物及其制备方法 |
| CN116270500B (zh) * | 2021-12-30 | 2025-05-06 | 安徽贝金基因科技有限公司 | 一种高稳定性的溶瘤病毒组合物及其制备方法和其应用 |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5626851A (en) | 1987-11-30 | 1997-05-06 | The Wistar Institute Of Anatomy And Biology | Rotavirus reassortant vaccine |
| US5096885A (en) | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
| DE69029765T2 (de) | 1989-07-24 | 1997-05-15 | Bayer Ag | Stabilisierung von hochgereinigten Proteinen |
| CA2132328C (en) | 1992-03-24 | 2000-10-31 | Laszlo K. Csatary | Vaccine containing live virus for therapy of viral diseases and malignancies |
| CA2075521C (en) * | 1992-05-05 | 1995-11-28 | Kuniaki Koyama | Stabilized live vaccine |
| JPH09504429A (ja) | 1993-10-12 | 1997-05-06 | チロン ビアジーン，インコーポレイティド | 組換えウイルスの保存方法 |
| JP3863559B2 (ja) | 1994-05-16 | 2006-12-27 | メルク エンド カンパニー インコーポレーテッド | 乳頭腫ウィルスワクチン |
| US7150984B2 (en) | 1994-07-11 | 2006-12-19 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuated human rotavirus vaccine |
| US6586006B2 (en) | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
| US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| GB9521806D0 (en) | 1995-10-25 | 1996-01-03 | Cortecs Ltd | Preservation methods |
| US6165773A (en) | 1995-10-25 | 2000-12-26 | Provalis Uk Limited | Methods of preserving viruses |
| FR2742756B1 (fr) | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
| FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| US5932223A (en) * | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| EP0939648B1 (en) | 1996-09-26 | 2007-11-07 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| US6403098B1 (en) | 1996-09-26 | 2002-06-11 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| US6616931B1 (en) | 1996-09-26 | 2003-09-09 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US6544769B1 (en) | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
| US20080261289A1 (en) | 1996-12-13 | 2008-10-23 | Schering-Plough Corporation | Compositions comprising viruses and methods for concentrating virus preparations |
| US6290967B1 (en) | 1996-12-20 | 2001-09-18 | Merck & Co., Inc. | Stabilizers for lyophilized vaccines |
| US6051238A (en) | 1996-12-20 | 2000-04-18 | Merck & Co., Inc. | Stabilizers for lyophilized mumps vaccines |
| JP2000507963A (ja) | 1996-12-20 | 2000-06-27 | メルク エンド カンパニー インコーポレーテッド | 凍結乾燥ワクチン用安定剤 |
| KR100912362B1 (ko) | 1998-02-17 | 2009-08-19 | 쉐링 코포레이션 | 바이러스 제제의 정제방법 |
| GB9808922D0 (en) * | 1998-04-24 | 1998-06-24 | Cantab Pharmaceuticals Res Ltd | Virus preparations |
| CN101318016B (zh) | 1998-07-28 | 2013-06-19 | 由卫生与公众服务部代表的美利坚合众国 | 多价人-牛轮状病毒疫苗 |
| CN1062770C (zh) * | 1998-11-12 | 2001-03-07 | 卫生部长春生物制品研究所 | 甲肝-麻疹二联疫苗及其生产方法 |
| DE69940354D1 (de) | 1998-11-16 | 2009-03-12 | Introgen Therapeutics Inc | Adenovirus-formulierungen zur gentherapie |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| WO2000061184A2 (en) | 1999-04-08 | 2000-10-19 | Glenn Gregory M | Dry formulation for transcutaneous immunization |
| PL364983A1 (en) | 1999-08-24 | 2004-12-27 | Teva Pharmaceutical Industries, Ltd. | A vaccine composition and method of using the same |
| US6592869B2 (en) | 1999-08-24 | 2003-07-15 | Teva Pharmaceutical Industries, Ltd. | Vaccine composition and method of using the same |
| DE60025019T2 (de) | 1999-10-29 | 2006-08-24 | Nektar Therapeutics, San Carlos | Trockenpulverzusammensetzungen mit verbesserter dispersivität |
| EP2420247A1 (en) | 2000-03-07 | 2012-02-22 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
| US7456009B2 (en) * | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| EP1289494A2 (en) | 2000-06-08 | 2003-03-12 | Powderject Vaccines, Inc. | Powder compositions |
| US20020120228A1 (en) | 2000-06-08 | 2002-08-29 | Yuh-Fun Maa | Powder compositions |
| TWI289158B (en) | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
| GB0020089D0 (en) | 2000-08-15 | 2000-10-04 | Smithkline Beecham Biolog | Vaccine Composition |
| US7494659B2 (en) | 2000-09-25 | 2009-02-24 | Polymun Scientific Immunbiologische Forschung Gmbh | Live attenuated influenza vaccine |
| US20040033239A1 (en) | 2001-03-06 | 2004-02-19 | Evans Robert K | Adenovirus formulations |
| DK2253701T3 (da) | 2001-03-16 | 2014-10-20 | Oncolytics Biotech Inc | Fremgangsmåde til ekstraktion af en virus fra en cellekultur |
| CA2449593A1 (en) | 2001-06-08 | 2002-12-19 | Powderject Vaccines, Inc. | Spray freeze-dried compositions |
| GB0124710D0 (en) | 2001-10-15 | 2001-12-05 | Quadrant Healthcare Uk Ltd | Therapeutic composition |
| CN1607941A (zh) | 2001-11-19 | 2005-04-20 | 贝克顿迪肯森公司 | 粒状药物组合物 |
| EP1453536A4 (en) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | COMPOSITION FOR PRESERVING VIRUSES |
| US20030153065A1 (en) | 2002-01-14 | 2003-08-14 | Genvec, Inc. | Composition and method for maintaining non-enveloped viral vectors |
| AR038153A1 (es) | 2002-01-18 | 2004-12-29 | Schering Ag | Formulaciones estabilizadas de adenovirus |
| WO2003086443A1 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| US7923029B2 (en) | 2002-04-11 | 2011-04-12 | Medimmune Llc | Spray freeze dry of compositions for pulmonary administration |
| US7135180B2 (en) | 2002-04-11 | 2006-11-14 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| CA2482512C (en) | 2002-04-30 | 2011-09-20 | Oncolytics Biotech Inc. | Improved viral purification methods |
| EP2395073B1 (en) | 2002-11-01 | 2017-09-06 | GlaxoSmithKline Biologicals S.A. | Drying process |
| US6752740B2 (en) | 2002-11-12 | 2004-06-22 | Jeffery T. Semmes | Continuously variable transmission |
| KR20050088175A (ko) | 2002-12-17 | 2005-09-02 | 메드이뮨 백신즈 인코포레이티드 | 생물활성 물질의 고압 분무 건조 |
| US6931888B2 (en) | 2003-02-07 | 2005-08-23 | Ferro Corporation | Lyophilization method and apparatus for producing particles |
| ES2529736T3 (es) | 2003-04-10 | 2015-02-25 | Novartis Vaccines And Diagnostics, Inc. | Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS |
| EP1660123B1 (en) * | 2003-09-02 | 2013-03-13 | GlaxoSmithKline Biologicals s.a. | Rotavirus vaccine |
| US20070148765A1 (en) | 2003-11-19 | 2007-06-28 | Evans Robert K | Preservative-containing virus formulations |
| EP1701738B1 (en) | 2003-12-17 | 2015-03-11 | Wyeth LLC | Method for producing storage stable RSV compositions |
| WO2005066333A1 (en) | 2003-12-30 | 2005-07-21 | Aventis Pasteur, Inc. | Stabilizing compositions for recombinant viruses |
| GB0404586D0 (en) | 2004-03-01 | 2004-04-07 | Britannia Pharmaceuticals Ltd | Improvements in or relating to organic materials |
| EP1720519A1 (en) | 2004-03-04 | 2006-11-15 | Wyeth | Lyophilization method to improve excipient crystallization |
| ES2644416T3 (es) | 2004-06-02 | 2017-11-28 | Universal Stabilization Technologies, Inc. | Conservación mediante vaporización |
| WO2006029467A1 (en) | 2004-09-16 | 2006-03-23 | Btf Pty Ltd | Rapid freeze drying process |
| TW200626177A (en) | 2004-09-28 | 2006-08-01 | Alza Corp | Method and formulation for stabilizing alum-adsorbed vaccines |
| US7901921B2 (en) | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
| MX2007005379A (es) * | 2004-11-05 | 2007-07-04 | Wellstat Biologics Corp | Formulaciones de virus envueltos estables y filtrables. |
| ATE406140T1 (de) | 2004-12-09 | 2008-09-15 | Precimed Sa | Operationsinstrumentenhalter für leichtere sterilisation |
| US20060141483A1 (en) * | 2004-12-23 | 2006-06-29 | Calton Gary J | Stabilization of viral compositions |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| PT1954308E (pt) * | 2005-09-16 | 2011-11-03 | Merial Ltd | Estabilizadores para vacinas liofilizadas |
| CN1765181A (zh) | 2005-10-19 | 2006-05-03 | 路兴波 | 高效抗病毒制剂 |
| PL2007883T3 (pl) | 2006-04-20 | 2012-07-31 | Wyeth Llc | Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| EP1854478A1 (en) | 2006-05-12 | 2007-11-14 | Cytos Biotechnology AG | Nicotine-carrier vaccine formulation |
| EP1878791A1 (en) | 2006-07-11 | 2008-01-16 | Bia Separations D.O.O. | Method for influenza virus purification |
| EP2055311B1 (en) | 2006-08-07 | 2017-06-21 | The Chemo-Sero-Therapeutic Research Institute | Process for preparing live smallpox vaccine |
| US20100129379A1 (en) | 2006-09-25 | 2010-05-27 | John Carpenter | Stabilized antibody formulations and uses thereof |
| NZ576563A (en) | 2006-11-03 | 2012-09-28 | Alphavax Inc | Alphavirus and alphavirus replicon particle formulations and methods |
| CL2007003209A1 (es) * | 2006-11-07 | 2008-05-09 | Acambis Inc | Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion |
| EP2762163B1 (en) | 2006-12-27 | 2018-01-03 | Zoetis Services LLC | Methods of vaccine administration |
| US20080299182A1 (en) | 2007-03-01 | 2008-12-04 | Shuyuan Zhang | Methods and formulations for topical gene therapy |
| JP5577103B2 (ja) * | 2007-03-12 | 2014-08-20 | オンコリティクス バイオテク，インコーポレーテッド | 改変配列を有するレオウイルス |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| CA2681567C (en) * | 2007-03-22 | 2016-07-19 | The Regents Of The University Of Colorado, A Body Corporate | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
| EP2940129B1 (en) | 2007-04-06 | 2020-05-06 | Takeda Vaccines, Inc. | Methods and compositions for live attenuated viruses |
| AR066649A1 (es) | 2007-05-21 | 2009-09-02 | Oncolytics Biotech Inc | Reovirus mutantes y metodos de elaboracion y uso de los mismos |
| US8241886B2 (en) * | 2007-09-25 | 2012-08-14 | Aridis Pharmaceuticals | Formulations for preservation of rotavirus |
| EP2630966B1 (en) | 2007-10-12 | 2017-04-19 | Massachusetts Institute of Technology | Vaccine nanotechnology |
| WO2009056651A1 (en) | 2007-11-02 | 2009-05-07 | Cytos Biotechnology Ag | Angiotensin-carrier formulation |
| NZ585500A (en) | 2007-11-12 | 2012-06-29 | Theraclone Sciences Inc | Antibodies which bind to an epitope in the extracellular domain of the matrix 2 ectodomain polypeptide of an influenza virus |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| JP2011514337A (ja) * | 2008-02-25 | 2011-05-06 | ノババックス，インコーポレイテッド | 糖ガラス化ウィルス様粒子（ｖｌｐ） |
| WO2011026948A1 (en) * | 2009-09-03 | 2011-03-10 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| AU2011336413B2 (en) * | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
| MX349294B (es) * | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Formulaciones virales liofilizadas. |
| JP6029651B2 (ja) * | 2011-04-29 | 2016-11-24 | オンコリティクス バイオテク，インコーポレーテッド | ゲル浸透クロマトグラフィーを使用してウイルスを精製する方法 |
| JP6065096B2 (ja) | 2015-12-25 | 2017-01-25 | ダイキン工業株式会社 | 調湿装置 |
-
2011
- 2011-12-02 MX MX2013006169A patent/MX349294B/es active IP Right Grant
- 2011-12-02 ES ES11845053.5T patent/ES2630012T3/es active Active
- 2011-12-02 EP EP11845053.5A patent/EP2646052B1/en active Active
- 2011-12-02 US US13/309,901 patent/US9044498B2/en active Active
- 2011-12-02 JP JP2013542199A patent/JP6034797B2/ja active Active
- 2011-12-02 CA CA2819236A patent/CA2819236A1/en active Pending
- 2011-12-02 KR KR1020137016720A patent/KR102023207B1/ko active Active
- 2011-12-02 EA EA201390812A patent/EA201390812A1/ru unknown
- 2011-12-02 DK DK11845053.5T patent/DK2646052T3/en active
- 2011-12-02 WO PCT/US2011/063037 patent/WO2012075376A2/en not_active Ceased
- 2011-12-02 SG SG2013040811A patent/SG190419A1/en unknown
- 2011-12-02 TW TW100144335A patent/TW201233803A/zh unknown
- 2011-12-02 AU AU2011336410A patent/AU2011336410B2/en active Active
- 2011-12-02 CN CN201180062149.7A patent/CN103269716B/zh active Active
-
2013
- 2013-05-29 IL IL226646A patent/IL226646B/en active IP Right Grant
-
2015
- 2015-04-22 US US14/693,100 patent/US9610352B2/en active Active
-
2016
- 2016-09-01 JP JP2016170628A patent/JP6433954B2/ja active Active
-
2018
- 2018-08-17 JP JP2018153546A patent/JP2018172443A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2819236A1 (en) | 2012-06-07 |
| JP6034797B2 (ja) | 2016-11-30 |
| CN103269716B (zh) | 2015-05-27 |
| WO2012075376A2 (en) | 2012-06-07 |
| JP6433954B2 (ja) | 2018-12-05 |
| MX2013006169A (es) | 2013-10-28 |
| US9610352B2 (en) | 2017-04-04 |
| JP2016199591A (ja) | 2016-12-01 |
| JP2013544288A (ja) | 2013-12-12 |
| EP2646052B1 (en) | 2017-03-29 |
| EP2646052A4 (en) | 2014-01-08 |
| JP2018172443A (ja) | 2018-11-08 |
| US9044498B2 (en) | 2015-06-02 |
| US20150224198A1 (en) | 2015-08-13 |
| MX349294B (es) | 2017-07-21 |
| CN103269716A (zh) | 2013-08-28 |
| WO2012075376A3 (en) | 2012-08-16 |
| SG190419A1 (en) | 2013-06-28 |
| DK2646052T3 (en) | 2017-07-17 |
| KR20140014096A (ko) | 2014-02-05 |
| ES2630012T3 (es) | 2017-08-17 |
| US20120141528A1 (en) | 2012-06-07 |
| AU2011336410B2 (en) | 2015-01-22 |
| EP2646052A2 (en) | 2013-10-09 |
| IL226646B (en) | 2018-02-28 |
| KR102023207B1 (ko) | 2019-11-25 |
| AU2011336410A1 (en) | 2013-03-28 |
| TW201233803A (en) | 2012-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201390812A1 (ru) | Лиофилизированные вирусные составы | |
| EA201390810A1 (ru) | Жидкие вирусные составы | |
| CY1119284T1 (el) | ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs) | |
| EA201190327A1 (ru) | Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv | |
| EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
| MY156422A (en) | Methods and compositions for live attenuated viruses | |
| EA201591888A1 (ru) | Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов | |
| MX358836B (es) | Proteinas f del vrs modificadas y metodos de uso de las mismas. | |
| MX2013010620A (es) | Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo. | |
| AR069882A1 (es) | Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e | |
| CO6440541A2 (es) | Virus de diarrea viral bovina con una proteina erns modificada | |
| PH12015500612A1 (en) | Subunit immersion vaccines for fish | |
| JO3281B1 (ar) | مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي | |
| PH12015501378A1 (en) | Porcine parvovirus 5a, methods of use and vaccine | |
| EA201491969A1 (ru) | Иммуногенные соединения, включающие пептид gp41 вич, связанный с белком-носителем crm197 | |
| BR112015031226A2 (pt) | Composição de vacina, e, uso da composição de vacina | |
| PH12015501721A1 (en) | Porcine parvovirus 5b, methods of use and vaccine | |
| WO2014140166A3 (en) | Vaccine | |
| MX2017008342A (es) | Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas. | |
| WO2012078051A3 (en) | IPN Vaccine | |
| EA201270798A1 (ru) | Соединения для лечения гепатита с | |
| MA35303B1 (fr) | Vaccin contre la rhinite equine | |
| GB201008123D0 (en) | Novel compounds | |
| MX2024003507A (es) | Mutantes del virus de la influenza b y usos de los mismos. | |
| EA201390452A1 (ru) | Вакцина |